Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedSep 15, 2025
DataAggregated Company Financials
Companies21
  • 7D0.4%
  • 3M-22.4%
  • 1Y-56.7%
  • YTD-39.5%

Over the last 7 days, the Healthcare industry has remained flat, although notably Zealand Pharma declined by 8.1%. Unfortunately though, the industry is down 57% over the past 12 months. Earnings are forecast to grow by 8.8% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 15 Sep 2025DKK 2.0tDKK 447.3bDKK 141.7b19.9x14.4x4.6x
Wed, 13 Aug 2025DKK 1.9tDKK 434.7bDKK 132.4b29x14.1x4.3x
Fri, 11 Jul 2025DKK 2.5tDKK 423.1bDKK 124.5b30.3x19.9x5.9x
Sun, 08 Jun 2025DKK 2.7tDKK 423.8bDKK 124.7b30.7x21.3x6.3x
Tue, 06 May 2025DKK 2.5tDKK 409.3bDKK 121.3b22.3x20.7x6.1x
Thu, 03 Apr 2025DKK 2.5tDKK 409.5bDKK 121.3b23.3x20.8x6.2x
Sat, 01 Mar 2025DKK 3.4tDKK 410.1bDKK 121.4b28.6x27.9x8.3x
Mon, 27 Jan 2025DKK 3.3tDKK 387.4bDKK 111.3b29.4x29.8x8.6x
Wed, 25 Dec 2024DKK 3.3tDKK 387.4bDKK 111.3b29.7x29.5x8.5x
Fri, 22 Nov 2024DKK 3.8tDKK 387.4bDKK 111.3b31.2x33.8x9.7x
Sun, 20 Oct 2024DKK 4.2tDKK 372.1bDKK 107.2b37.1x38.8x11.2x
Tue, 17 Sep 2024DKK 4.7tDKK 371.9bDKK 107.1b36.5x44x12.7x
Thu, 15 Aug 2024DKK 4.6tDKK 370.3bDKK 106.9b36.8x43.4x12.5x
Sat, 13 Jul 2024DKK 4.9tDKK 355.2bDKK 106.2b35.5x46.6x13.9x
Mon, 10 Jun 2024DKK 4.9tDKK 355.3bDKK 106.2b36.2x46.5x13.9x
Wed, 08 May 2024DKK 4.5tDKK 355.3bDKK 106.5b35x42.3x12.7x
Fri, 05 Apr 2024DKK 4.4tDKK 341.2bDKK 99.6b38x44.4x13x
Sun, 03 Mar 2024DKK 4.4tDKK 340.0bDKK 98.9b38x44.4x12.9x
Tue, 30 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b33.7x42.7x12x
Thu, 28 Dec 2023DKK 3.6tDKK 320.4bDKK 90.0b33.1x40x11.2x
Sat, 25 Nov 2023DKK 3.7tDKK 320.5bDKK 90.0b32.8x41.2x11.6x
Mon, 23 Oct 2023DKK 3.5tDKK 305.5bDKK 82.2b27.8x42.6x11.5x
Wed, 20 Sep 2023DKK 3.4tDKK 305.5bDKK 82.2b35.4x41.7x11.2x
Fri, 18 Aug 2023DKK 3.4tDKK 302.9bDKK 81.1b37.7x41.6x11.1x
Sun, 16 Jul 2023DKK 2.9tDKK 286.9bDKK 75.4b39x38.6x10.1x
Tue, 13 Jun 2023DKK 3.0tDKK 287.1bDKK 75.5b40.1x40x10.5x
Thu, 11 May 2023DKK 3.1tDKK 285.5bDKK 74.7b41x42.1x11x
Sat, 08 Apr 2023DKK 3.0tDKK 272.4bDKK 68.5b39.4x43.5x10.9x
Mon, 06 Mar 2023DKK 2.8tDKK 292.6bDKK 69.2b39.4x40.7x9.6x
Wed, 01 Feb 2023DKK 2.7tDKK 275.9bDKK 66.3b37.1x40.2x9.7x
Fri, 30 Dec 2022DKK 2.7tDKK 276.0bDKK 66.3b37.3x40.5x9.7x
Sun, 27 Nov 2022DKK 2.5tDKK 276.2bDKK 66.3b36.6x37.8x9.1x
Tue, 25 Oct 2022DKK 2.3tDKK 261.3bDKK 62.4b34.9x36.9x8.8x
Thu, 22 Sep 2022DKK 2.2tDKK 261.3bDKK 62.4b33.9x36x8.6x
Price to Earnings Ratio

36x


Total Market Cap: DKK 2.2tTotal Earnings: DKK 62.4bTotal Revenue: DKK 261.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 36.4x202320242025
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 14.4x which is lower than its 3-year average PE of 36.4x.
  • The 3-year average PS ratio of 10.0x is higher than the industry's current PS ratio of 4.6x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 31% per year over the last three years.
  • Revenues for these companies have grown 20% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market0.24%
Healthcare0.38%
Life Sciences5.79%
Healthcare Services1.90%
Biotech0.62%
Pharma0.52%
Medical Equipment-1.09%
Healthtech-5.63%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 23.7x.
    • Analysts are expecting annual earnings growth of 60.4%, which is higher than its past year's earnings decline of 47.6% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 89% over the next 5 years.
  • In contrast, the Biotech industry is expected to see its earnings decline by 8.4% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 355.102.3%
+DKK 36.2b		-61.5%PE14.2x
GMAB GenmabDKK 1.78k2.1%
+DKK 2.3b		-0.06%PE12.6x
CHEMM ChemoMetecDKK 631.5017.8%
+DKK 1.7b		51.7%PE59x
HLUN B H. LundbeckDKK 42.362.7%
+DKK 1.1b		-6.9%PE12x
ALK B ALK-AbellóDKK 206.202.2%
+DKK 973.2m		14.4%PE45.7x

Latest News

NOVO B
DKK 355.10
Novo Nordisk
7D
2.3%
1Y
-61.5%
CHEMM
DKK 631.50
ChemoMetec
7D
17.8%
1Y
51.7%
EMBLA
DKK 30.50
Embla Medical hf
7D
-1.6%
1Y
-1.0%
GMAB
DKK 1,775.50
Genmab
7D
2.1%
1Y
-0.06%
NNIT
DKK 59.50
NNIT
7D
-4.8%
1Y
-49.1%
ZEAL
DKK 428.30
Zealand Pharma
7D
-4.5%
1Y
-53.2%

Clinical Catalysts And Roche Alliance Will Advance Obesity Amid Risks

Analysts maintain a positive long-term outlook on Zealand Pharma despite near-term competitive and pipeline risks, leading to a modest consensus price target reduction from DKK835.47 to DKK818.80 as updated risk assessments are incorporated. Analyst Commentary Bullish analysts cite attractive entry points at current share levels, suggesting the stock is undervalued given long-term growth potential.
DEMANT
DKK 244.60
Demant
7D
-2.0%
1Y
-13.3%

Aging Demographics And Hearing Care Awareness Will Shape Future Progress

Analysts have maintained an upbeat outlook on Demant due to increased confidence in its guidance, improved fundamentals, and decreased downside risks, resulting in the consensus price target holding steady at DKK291.50. Analyst Commentary Improved confidence in Demant's ability to achieve its guidance, considered more achievable compared to peers.
HLUN B
DKK 42.36
H. Lundbeck
7D
2.7%
1Y
-6.9%

CNS Pipeline And Global Expansion Will Unlock Future Opportunities

With both future P/E and consensus revenue growth forecasts essentially unchanged, there has been no meaningful revision to H. Lundbeck's analyst price target, which remains at DKK48.18.
ALK B
DKK 206.20
ALK-Abelló
7D
2.2%
1Y
14.4%
COLO B
DKK 610.00
Coloplast
7D
-1.9%
1Y
-35.2%

Chronic Care Focus And Emerging Markets Will Redefine Healthcare

Coloplast’s consensus price target was modestly reduced to DKK718.06 as analysts weighed concerns about slowing revenue growth and margin pressure against stable demand in key product portfolios and longer-term benefits from innovation and expansion. Analyst Commentary Bearish analysts cite concerns over slowing revenue growth and margin pressure, particularly in core European markets.
BAVA
DKK 232.60
Bavarian Nordic
7D
-1.7%
1Y
-6.4%

VIMKUNYA Launch Will Open Markets, But Approval Delays Could Impact Revenues

Despite a deterioration in consensus revenue growth forecasts, a modest improvement in net profit margin has supported a slight increase in Bavarian Nordic's fair value, with the target price rising from DKK234.50 to DKK244.00. What's in the News Nordic Capital and Permira have proposed to acquire Bavarian Nordic for DKK 18.1 billion (DKK 233 per share), a 21% premium to the prior closing price; board and management have agreed to tender their shares, and a delisting is planned upon completion, subject to customary conditions.
AMBU B
DKK 97.35
Ambu
7D
-0.6%
1Y
-25.8%

Ambu A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 27
Ambu A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
GUBRA
DKK 393.60
Gubra
7D
-0.6%
1Y
-25.7%
BRAINP
DKK 0.014
Brain+
7D
15.3%
1Y
-83.4%